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Herein, we summarize our recent findings from the international Collaborative Transplant Study (CTS) and Heidelberg Transplant
Center regarding the role of HLA antibodies in kidney transplantation and their application into the clinical routine. Based on the
antibody findings from the CTS serum study, an algorithm was developed in 2006 for the transplantation of high-risk sensitized
patients at the Heidelberg Transplant Center which includes seven different pre- and posttransplant measures. Using this
algorithm, the number of transplantations could be increased in high-risk presensitized patients and the previously existing
impact of antibodies on graft survival could greatly be diminished but not totally eliminated. More recent findings led to the
hypothesis that T cell help from a preactivated immune system supports the harmful effects of pretransplant donor-specific
HLA antibodies that otherwise disappear in many cases after transplantation without any consequence.
1. Introduction
Although effective therapies to treat antibody-mediated
rejection (AMR) still need to be developed, with his vision
and strong determination, Paul Ichiro Terasaki was the driv-
ing force that convinced the transplant community to perform
the necessary studies to comprehend the different aspects of
humoral rejection in kidney transplantation. We dedicate
this article therefore to this great scientist.
Thanks to the introduction of the single-antigen bead
technique (SAB), which allows detection of HLA antibodies
with high sensitivity, and improvement of pathological diag-
nosis, we widely understand today the role of donor-specific
HLA antibodies (DSA) in the posttransplant phase. How-
ever, in which patients pretransplant DSA would exert their
harmful effects is still not fully understood. Many patients
were transplanted in the past in the presence of preexisting
DSA; not all of them lost their grafts, even if the DSA was
strong and complement-activating [1–3]. Pretransplant
DSA disappear in many patients without any clinical conse-
quence directly after transplantation, whereas in others, even
weak pretransplant DSA persist and do harm in the subse-
quent course [3, 4].
2. Presensitization as a Major Problem
Kidney transplantation of presensitized patients with HLA
antibodies in their serum is challenging mainly for two
reasons. (1) To prevent a positive preoperative complement-
dependent cytotoxicity (CDC) crossmatch result and dimin-
ish the harmful effects of pretransplant DSA, unacceptable
HLA antigen mismatches are determined using sensitive
assays and in the consequencemany organ offers are excluded
for these patients already at the virtual crossmatch level.
Without further measures, presensitized patients accumulate
on the kidney waiting list and face prolonged waiting times.
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(2) Even when the pretransplant CDC crossmatch result is
negative and the patient is successfully transplanted, long-
term graft survival may be impaired in these patients, due to
either persistence or reappearance of pretransplant DSA in
the posttransplant phase or development of de novo DSA
which can cause antibody-mediated tissue injury.
3. Heidelberg Algorithm for Transplantation of
Presensitized High-Risk Patients
To overcome these two major problems, we introduced in
April 2006 an algorithm for the transplantation of presensi-
tized high-risk kidney transplant recipients at our center
and adapted it further in 2007, 2009, and 2016 [3, 5–7]. A total
of seven different measures are used in an integrated fashion
to transplant these patients in a reasonable period of timewith
improved outcomes (Table 1). As shown in Figure 1(a), pre-
sensitized patients with ELISA-reactive HLA antibodies who
were transplanted in the years 2000 to 2007 showed signifi-
cantly lower graft survival rates than patients without
ELISA-reactive HLA antibodies. This difference disappeared
after the introduction of the Heidelberg Algorithm although
more high-risk patients were transplanted (Figure 1(b)).
The most critical components of our integrative
approach are the pretransplant identification of high-risk
patients on the waiting list (measure 1) and the risk-
stratified organ allocation (measures 2 and 3). For example,
a patient who has a high cytotoxic PRA and/or is positive
for both class I and II HLA antibodies in ELISA (measure
1) is at increased risk of graft loss. We reported in two inde-
pendent series of 4136 and 5315 kidney transplant recipients
on the increased risk of graft loss in the presence of pretrans-
plant class I and class II HLA antibodies, as measured by
ELISA [8, 9]. These patients may be successfully and timely
transplanted when only a low number of HLA mismatches
are present (measure 2) [9], and the transplantation is per-
formed via the Eurotransplant Acceptable Mismatch pro-
gram which allocates organs to highly immunized patients
with high priority (measure 3) [10]. Since October 2016, pre-
transplant determination of the immune activation marker
soluble CD30 (sCD30) in ELISA has also become an impor-
tant component of pretransplant risk estimation in measure
1 of the Heidelberg Algorithm because pretransplant activa-
tion of the immune system, as measured by high sCD30
levels, was in two recent studies of 80 presensitized high-
risk patients from Heidelberg and 385 presensitized patients
from 13 transplant centers (corresponding to a series of some
1000 patients) found to be a substantial risk factor for graft
loss in the presence of DSA (see below) [3, 7].
All as “high-risk”-categorized patients receive, during a
deceased-donor organ offer process or in preparation for
transplantation from a living donor, pre- and postoperative
apheresis treatment (measures 4 and 5) to bring undetected
antibody to a lower level and to prevent antibody-mediated
allograft injury due to an early rebound of preexisting DSA.
To prevent the development of de novo DSA, this is com-
bined with the administration of anti-B cell antibody rituxi-
mab (measure 4). B cells are important antigen-presenting
cells and are critical for T cell activation and the development
of T cell memory during alloimmune responses. Despite a
lack of effect against long-lived plasma cells, in some reports,
anti-CD20 therapy was associated with a reduction of DSA
reactivity. Rituximab may prevent the generation of
antibody-producing cells from the naive B cell pool and
may target short-lived plasma cells that express CD20 on
their surface. In addition, anti-CD20 therapy may deplete B
cell aggregates within allografts. Kohei et al. reported on
1.7% and 18.1% de novo DSA rates in patients, after ABO-
incompatible or ABO-compatible kidney transplantation,
indicating that targeting B cell immunity at the time of trans-
plantation with rituximab may reduce antibody-mediated
allograft injury during the subsequent course [11]. In our first
series of 34 high-risk patients, severe cellular rejection was
Table 1: “Heidelberg Algorithm” (applied since April 2006).
(1) Pretransplant identification of high-risk patients
Donor-independent
(i) CDC-PRA-DTT ≥85% (current or historical)
(ii) HLA class I and II antibody positivity in ELISA
(iii) HLA class I positivity in ELISA (retransplant)
Donor-dependent
(i) Positive CDC B-cell crossmatch in retransplant recipients
with HLA class II antibody positivity in ELISA
(ii) Positive CDC T-cell crossmatch
(iii) DSA ≥1,000 MFI (living donor; since April 2009)
(iv) DSA ≥1,000 MFI and sCD30≥ 80 ng/ml (since October
2016)
(2) Good HLA match in patients with HLA class I and class II
antibody positivity in ELISA (deceased donor)
(i) CDC-PRA-DTT ≥10%: 0-1 HLA-A, -B, -DR mismatches
(ii) CDC-PRA-DTT <10%: 0-2 HLA-A, -B, -DR mismatches
(3) Acceptable Mismatch Program of Eurotransplant (deceased
donor)
(i) CDC-PRA-DTT ≥85% (current or historical)
(4) Pretransplant treatment
(i) Single plasmapheresis (deceased donor)
(ii) Repeated immunoadsorption (living donor)
(iii) Triple immunosuppression (tacrolimus + enteric-coated
mycophenolic sodium + methylprednisolone; in the case of
living donor, together with the initiation of apheresis
therapy)
(iv) Rituximab 375mg/m2 (when all crossmatches are negative)
(v) Thymoglobulin 1.5mg/kg body weight preoperatively and a
median of 2 times (range: 1–6) postoperatively (since April
2009; IL-2 receptor antagonist basiliximab beforeApril 2009)
(5) Posttransplant treatment
(i) Repeated plasmapheresis (deceased donor)
(ii) Repeated immunoadsorption (living donor)
(6) Protocol biopsies
(i) On days 7 and 90 (since November 2007)
(7) Posttransplant monitoring of DSA
(i) On days 0, 7, 30, 180, and every 6 months thereafter
(ii) If deterioration of allograft function
(iii) C1q assay if DSA ≥3,000 MFI (since March 2016)
Adopted from [5]. CDC: complement-dependent cytotoxicity; PRA: panel
reactive antibodies; DTT: dithiothreitol; DSA: donor-specific HLA
antibodies; sCD30: soluble CD30.
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infrequent under the usage of rituximab, even in the absence
of thymoglobulin, while borderline changes were found fre-
quently [5]. Since 2009, high-risk patients in addition receive
T cell-eliminating induction therapy by thymoglobulin to
target an early T cell response which would support de novo
DSA and C1q-DSA development (see below). Protocol biop-
sies at days 7 and 90 (measure 6) and posttransplant antibody
monitoring (measure 7) to diagnose AMR after successful
kidney transplantation in its earlier stages complete the
Heidelberg Algorithm.
Posttransplant antibody monitoring has recently been
further refined with the introduction of the C1q assay.
Patients with high mean fluorescence intensity (MFI) DSA
of greater than 3000 are automatically tested since March
2016 for the presence of complement C1q component-
binding DSA. We also consider posttransplant appearance
of C1q-DSA a major risk factor for AMR-mediated graft loss
during the further course (see below) [2–4].
Using this approach, even high-risk sensitized patients
can be transplanted with graft survival rates that are not
different from those of nonsensitized kidney recipients. In
our initial analysis, 1-year graft survival, death-censored graft
survival, and patient survival rates in 28 deceased donor
kidney recipients were 92%, 96%, and 96%, respectively,
and no graft loss or patient death was observed in the 6
living-donor kidney recipients [5]. AMR occurred in 1 living
and 2 deceased donor kidney transplant recipients during the
follow-up. However, the rate of cellular rejections (including
borderline changes) in kidney graft biopsies and delayed graft
function (DGF) were with 79% and 41%, respectively, quite
high. We had previously reported that besides increased cold
ischemia time, HLA antibodies and mild forms of AMR may
also be involved in DGF [12]. To reduce this high rate of cel-
lular rejection that may initiate AMR and DGF, interleukin-2
receptor antibody induction therapy was substituted by more
potent thymoglobulin induction in high-risk sensitized
patients from April 2009. This therapy is accompanied by
rigorous infection prophylaxis by valganciclovir (when the
donor is CMV-positive) and cotrimoxazole (in all patients).
4. Association of Posttransplant DSA with
Graft Loss
We addressed the clinical value of posttransplant DSA mon-
itoring which is the seventh measure of the Heidelberg Algo-
rithm in three different cohorts: (1) in the CTS serum study,
(2) in the Heidelberg pediatric cohort, and (3) in the Heidel-
berg presensitized high-risk population that was transplanted
using the Heidelberg Algorithm.
4.1. CTS Data on the Impact of Posttransplant DSA. In the
CTS serum study, we investigated a possible association of
de novo development and persistence or loss of preexisting
DSA with graft failure in 83 patients with failed kidney trans-
plants and in 83 control patients without graft loss who were
matched for eight different parameters, including the time
after transplantation [4]. We chose this study design, because
DSA determinations are costly and graft loss has increasingly
become a rare event, and we wanted to include as many
patients with graft loss into the analysis as possible. Eighty-
three patients with graft loss correspond to a series of some
1000 transplant recipients. Antibody reactivity at five differ-
ent cutoffs (500, 1000, 2000, 3000, and 5000 MFI) was evalu-
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Figure 1: Graft survival in patients with and without ELISA-reactive HLA antibodies who were transplanted at the Heidelberg Transplant
Center between 2000 and 2007 (a) and after 2007 (b). Ab: ELISA-reactive HLA antibody.
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allowed the precise determination of DSA against 10 different
HLA loci.
In this study, the rate of de novo DSA and also non-DSA
with ≥500 MFI was higher in the graft loss than in the non-
rejector group (76% versus 40%, p < 0 001). Because of the
low number of patients developing de novo DSA (22% of
patients with graft loss), the DSA results did not reach statis-
tical significance. At all cutoffs, there was a significantly
higher rate of de novo non-DSA in patients with graft loss,
which was explained rather by adsorption of DSA onto the
graft than epitope sharing. Furthermore, the incidence of
strong pretransplant DSA with 5000 MFI or higher that per-
sist after transplantation was also higher in the graft loss
group (10% versus 1%, p = 0 034).
The main problem in the clinical routine is that de novo
DSA appear also in patients without immediate graft loss.
When the C1q-binding ability of de novo or persistent DSA
was analyzed in sera of patients with and without graft loss,
none of the nonrejectors demonstrated C1q positivity,
whereas 43% of patients with graft loss showed C1q-
positive antibodies, although not necessarily donor-specific
(p < 0 001). Overall, our data from this study indicated that
the posttransplant presence of persisting or de novo HLA
antibodies, especially if strong and C1q-binding, is associated
with graft loss, even if the antibodies are not specific for
mismatched donor HLA [4].
4.2. Evaluation of Posttransplant DSA Monitoring in
Pediatric Patients with Indication Biopsy. Antibody effects
appear to be stronger in pediatric than adult recipients [13].
Therefore, we found it important to investigate also in our
pediatric cohort the diagnostic value of posttransplant DSA.
Sera of 62 patients who underwent clinically indicated
graft biopsies were tested for DSA, and their association with
specific histological lesions and subsequent graft outcome
was analyzed [14]. Twenty-six patients (42%) were DSA-
positive at the time of indication biopsy and nine (15%) of
them were in addition C1q-positive. At 4 years after biopsy,
the nine patients with C1q positivity showed a graft survival
rate of 11%, which was strikingly lower than the 88% and
82% survival rates in DSA-negative and DSA-positive but
C1q-negative patients, respectively (p < 0 001 and p = 0 001,
resp.) (Figure 2). The majority (89%) of C1q-positive patients
in this study were diagnosed with chronic active AMR. C1q-
positive DSA (adjusted hazard ratio (HR)= 6.4), presence of
transplant glomerulopathy (HR=9.5), and estimated glo-
merular filtration rate (eGFR) at the time of indication biopsy
(HR=0.9) were risk factors for subsequent graft loss. Thus,
the presence of C1q-positive DSA in the context of an indica-
tion biopsy identified a subgroup of pediatric renal transplant
recipients with a markedly increased risk of subsequent graft
loss. Because a fraction of DSA-positive patients escape rejec-
tion or graft dysfunction, the C1q assay appeared to increase
the specificity of a positive DSA result regarding unfavorable
transplant outcome.
4.3. Impact of Posttransplant DSA in the Heidelberg High-
Risk Collective. Our adult high-risk cohort which consists of
patients who are transplanted via the Heidelberg Algorithm
is a special population in which the antibody effects are
expected to occur in an accelerated manner. Compared to
that of the international CTS study, we have in this cohort
low number of patients with graft loss but more precise infor-
mation on individual patients. Recently, we analyzed 80 of
these high-risk sensitized patients who were transplanted at
our center from April 2006 to November 2011 with a mini-
mum follow-up for all patients of 36 months [3].
Despite all measures, seven patients developed AMR
and six of them lost their graft within the first 4 years after
transplantation, and all six patients were positive for C1q-
DSA (1 persistent, 4 de novo, and 1 persistent plus de novo
C1q-DSA) (Figure 3(a)).
In contrast to this striking association between posttrans-
plant C1q-DSA and AMR-related graft loss, the predictive
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Figure 2: Postbiopsy kidney graft survival in pediatric patients stratified according to the donor-specific HLA antibody- (DSA-) C1q status at
the time of indication biopsy. Patients with C1q-DSA positivity had a significantly inferior graft survival compared to patients without DSA
(p < 0 001). Patients with DSA but without C1q positivity showed comparable graft survival to DSA-negative patients (p = 0 55) but
significantly better graft survival than patients with C1q-DSA positivity (p = 0 001). Modified from [14].
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value of pretransplant C1q-DSA was, even in this high-risk
group, quite low. Of the 61 patients with pretransplant DSA
(cutoff 500 MFI), 14 patients possessed C1q-DSA (cutoff
300 MFI). AMR rates and AMR-related graft loss in patients
with pretransplant C1q-DSA were with 36% versus 28% and
14% versus 8%, respectively, not significantly different from
the rates in patients with C1q-negative DSA. Interestingly,
as many as 11 of 13 (85%) high-risk patients with pretrans-
plant C1q-DSA and a posttransplant serum lost their C1q-
DSA after surgery with an unremarkable clinical course,
which is in line with the findings of Otten et al. and Loupy
et al. that posttransplant but not pretransplant C1q-DSA pre-
dict AMR and AMR-related graft loss [1, 2].
5. Pretransplant DSA and sCD30
Earlier data from our group and others indicated that a pre-
activated immune system, as measured by sCD30, especially
in combination with HLA antibodies is a good indicator of
posttransplant rejection and graft loss [15–19]. Allostimula-
tion results in the upregulation of the T cell activation marker
CD30 on CD4 as well as CD8 memory T cells and increased
release of the 88 kD sCD30 from these cells in an IFN-γ- and
IL-2-dependent manner [20]. In the search for further bio-
markers to improve risk estimation before transplantation
as the basic component of Heidelberg Algorithm, we recently
investigated a possible association of sCD30, DSA, and
antibody-mediated graft loss in the group of 80 high-risk
sensitized patients. The risk for AMR-related graft loss in
18 patients who had both, a positive pretransplant DSA
value (cutoff 500 MFI) and a positive sCD30 value (cutoff
100ng/mL), was 11 times higher than that in the remaining
62 patients (HR=11.1, 95% CI 1.68 to 73.4, log-rank
P = 0 013) and 5.7 times higher than that in DSA-positive
but sCD30-negative patients (Figure 3(b)). Two patients
who were sCD30-negative pretransplant and experienced
AMR-related graft loss had a gap in immunosuppressive
therapy and became sCD30-positive (posttransplant cutoff
40 ng/mL) prior to their AMR episode [3].
To substantiate this finding, we analyzed the combined
impact of pretransplant DSA and the immune activation
marker sCD30 on a larger cohort of 385 presensitized kidney
transplant recipients from the CTS database who possessed
ELISA- or CDC-reactive HLA antibodies in their serum [7].
In this study, a deleterious influence of pretransplant DSA
(cutoff 1000 MFI) on 3-year graft survival was evident only
in patients who were positive (≥80 ng/mL) for the immune
activation marker sCD30. In the absence of sCD30 positivity,
3-year graft survival was almost identical in patients with or
without DSA (83% and 84%, P = 0 81). In contrast, a strik-
ingly lower 3-year graft survival rate of 62% was observed in
patients who were both sCD30- and DSA-positive (HR 2.9,
P < 0 001). Even in the presence of strong DSA with ≥5000
MFI, the 3-year graft survival rate was high if the recipients
were sCD30-negative. An update of these results in 411
patients is shown in Figure 4.
However, our findings on the clinical relevance of SAB-
detected pretransplant DSA and sCD30 are restricted to pre-
sensitized patients with CDC- or ELISA-reactive antibodies.
We reported previously on the missing association of SAB-
detected pretransplant DSA with graft loss in CDC- and
ELISA-negative kidney graft recipients [21], which could
partly be explained by false positive results due to reactivity
with denatured antigen on the beads that can be observed
in healthy individuals [22] as well as in kidney transplant
recipients without history of an immunizing event [23].
We hypothesize that patients with pretransplant DSA
and the activated immune system (as measured by pretrans-
plant sCD30) require special attention after kidney trans-
plantation. In these patients, a gap in immunosuppressive
therapy may lead to persistence, reappearence, or de novo
occurrence of strong, complement-activating DSA, resulting
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Figure 3: Graft loss from antibody-mediated rejection in high-risk sensitized patients with and without C1q-binding posttransplant donor-
specific HLA antibodies (DSA) (a) and in patients who in addition to pretransplant DSA positivity had also increased levels of the immune
activation marker sCD30 before transplantation (b).
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6. Conclusions
Integrated approaches are required for successful and timely
transplantation of presensitized high-risk patients. Estima-
tion of risk of graft failure prior to transplantation is impor-
tant and requires further precision by introduction of
additional biomarkers. Combination of DSA in presensitized
patients with CDC- or ELISA-reactive antibodies with the
immune activation marker sCD30 appears promising and
deserves further evaluation.
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